MicuRx(SH:688373)2025-01-16 07:46Revenue Projections - The company expects 2024 annual revenue to be approximately between 120 million and 140 million CNY, an increase of 29.22 million to 49.22 million CNY compared to the previous year, representing a growth of 32.19% to 54.23% year-on-year[3]. - The previous year's revenue was 90.78 million CNY[5]. Net Loss Projections - The projected net loss attributable to the parent company for 2024 is expected to be between 480 million and 440 million CNY, an increase in loss of 18.88 million to 58.88 million CNY compared to the previous year, reflecting a year-on-year increase in loss of 4.48% to 13.98%[3]. - The expected net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 is projected to be between 500 million and 460 million CNY, an increase in loss of 5.99 million to 45.99 million CNY compared to the previous year, indicating a year-on-year increase in loss of 1.32% to 10.13%[3]. - The previous year's net loss attributable to shareholders was 421.12 million CNY[6]. Business Growth Factors - The increase in main business revenue is attributed to the growth in the number of hospitals covered and the increase in prescription volume[8]. Expenses and Losses - The continued losses are primarily due to increased R&D expenses as clinical projects progress and higher sales expenses due to active sales efforts[9]. Financial Data and Risks - The financial data in this forecast has not been audited by registered accountants[4]. - The forecast data is preliminary and the accurate financial data will be disclosed in the audited 2024 annual report[11]. - Investors are advised to pay attention to investment risks related to the preliminary nature of the forecast data[11].